We previously reported that mutations in the -opioid receptor (MOR), S196L or S196A, rendered MOR responsive to the opioid antagonist naloxone without altering the agonist phenotype. Subsequently, a mouse strain carrying the S196A mutation exhibited in vivo naloxone antinociceptive activity without the development of tolerance. In this study we investigated the possibility of combining the in vivo site-directed delivery of MORS196A and systemic naloxone administration as a paradigm for pain management. Double-stranded adenoassociated virus type 2 (dsAAV2) was used to deliver MORS196A-EGFP by injecting the virus into the spinal cord (S2/S3) dorsal horn region of ICR mice. MORS196A-EGFP fluorescence colocalized with some calcitonin gene-related peptide and neuron-specific protein immunoreactivity in the superficial layers of the dorsal horn 1 week after injection and lasted for at least 6 months. In mice injected with the mutant receptor, morphine induced similar antinociceptive responses and tolerance development or precipitated withdrawal symptoms and reward effects, similar to those in the control mice (saline injected into the spinal cord). Conversely, in the dsAAV2-injected mice, naloxone produced antinociceptive effects at the spinal level but not at the supraspinal level, whereas naloxone had no measurable effect on the control mice. Furthermore, the chronic administration of naloxone to mice injected with dsAAV2-MORS196A-EGFP did not induce tolerance, dependence, or reward responses. Thus, our current approach to activate a mutant receptor, but not the endogenous receptor, with an opioid antagonist represents an alternative to the use of traditional opioid agonists for pain management.
morphine ͉ -opioid receptor ͉ naloxone M orphine activates the -opioid receptor (MOR) and produces an analgesic effect. For decades, morphine and its congeners have been used to control moderate and severe postoperative pain and cancer-associated pain. However, its many adverse effects, such as respiratory depression, vomiting, nausea, constipation, and, most noticeably, tolerance, dependence, and addiction, have hindered the use of this group of analgesic agents. It has been the holy grail of opioid pharmacologists to develop a pharmacological agent, a drug molecule that produces the desirable analgesic effects without any side effects.
Instead of exploring the development of novel drug molecules for this purpose, we decided to examine the possibility of using a mutant MOR as a therapeutic agent. Previously, we have reported that mutation of the Ser 196 residue in the fourth transmembrane domain of MOR to Leu or Ala resulted in opioid antagonists, such as naloxone or naltrexone, activating the mutant receptor (1) . In Chinese hamster ovary cells stably expressing the Ser 196 mutant, the inhibition of forskolinstimulated adenylyl cyclase activity by naloxone or naltrexone was observed, with no change in agonist potency or efficacy (1).
In Xenopus oocytes coexpressing the mutant opioid receptor and the G protein-coupled inwardly rectifying potassium channel (Kir3.1), the antagonists could also activate the channels (1) . The ability of opioid antagonists to activate MORS196A in vitro was also demonstrated in vivo. By generating homozygous MORS196A mutant mice by homologous recombination, we demonstrated the ability of the opioid antagonists naloxone and naltrexone to elicit antinociceptive responses in these MORS196A knockin mice (2) . The responses to the prototypic opioid agonist morphine remained unchanged in these mice. Although chronic treatment of these mice with morphine produced the expected tolerance and physical withdrawal responses, chronic naloxone or naltrexone treatment did not result in tolerance and physical withdrawal (2) . Such observations suggest that, if the MORS196A mutant can be delivered to the appropriate site within the pain pathway, opioid antagonist-mediated activation of this mutant receptor should result in pain control without the development of tolerance and dependence.
To achieve this goal, a gene-delivery vehicle must be chosen for neuronal expression of the mutant MORS196A receptor. The recombinant adenoassociated viral type 2 vector (rAAV2) is a promising tool in the context of gene therapy because of its extensive transduction into neurons, and rAAV2 can mediate long-term gene expression with no apparent toxicity. Its lack of immunogenicity or any known pathogenicity also means that the AAV vector has become a suitable choice for human clinical trials (3, 4) . AAV transgenic expression requires the conversion of the original ssDNA to the dsDNA genome, making the transduction rate less efficient both in vitro and in vivo. However, when the 5Ј end of the inverted terminal repeat is mutated, the resulting novel AAV vectors predominantly package the dsDNA genome (5) . The dsAAV vectors have been shown to achieve and accelerate more robust transgenic expression than the ssAAV vectors in vivo (5-7). Furthermore, the production of AAV by the adenovirus-free method simplifies the viral vector purification steps and the generation of a high titer of dsAAV (8) . Therefore, in this study, dsAAV2 was used to deliver the mutated MOR conjugated with the EGFP molecule (MORS196A-EGFP) by injecting the virus locally into the dorsal horn area within the S2/S3 region of wild-type ICR mice. After establishing the time course of viral expression in the dorsal horn neurons, the acute and chronic antinociceptive effects of mor-phine or naloxone were tested 4 weeks after gene transfer. The possibility of using naloxone to activate the delivered mutant MOR in pain control, with minimal side effects, was then examined.
Results

DsAAV2MORS196A-EGFP Gene Transfer and Expression in Vivo.
To monitor the expression of the mutant MOR, we constructed a vector that expressed an EGFP fusion protein in which EGFP was spliced to the MORS196A C terminus. This fusion protein was shown to locate to the plasma membrane and exhibited a pharmacological profile identical to that of the mutant receptor without EGFP when expressed in several in vitro cell models. When dsAAV2 containing the MORS196A-EGFP construct was injected bilaterally into the spinal cord (S2/S3) of ICR mice, we observed significant EGFP fluorescence within the vicinity of the needle tract in the S2/S3 spinal cord dorsal horn region 1 week to 6 months after gene transfer. This EGFP fluorescence was found to diffuse 4-6 mm from the injection site (up to L2 or L3 and down to at least to Co2) and was trapped in the dorsal part of the spinal cord. We also examined the nearby dorsal root ganglia (DRGs) and found significant amounts of EGFP fluorescence at L2/L3 DRG, which means that the virus had diffused to the nearby DRGs. The cells expressing MORS196A-EGFP in the DRG included small, intermediate, and large neurons.
To determine the cell types that expressed the MORS196A-EGFP, spinal cord slices at the S2/S3 level were then stained for the neuron-specific protein (NeuN) or calcitonin gene-related peptide (CGRP), a well characterized marker of sensory neurons within the DRG and related afferent fiber terminals (9, 10) . As shown in Fig. 1 A and B , colocalization of EGFP and CGRP immunofluorescence was observed in the superficial layer of the dorsal horn in the S3 spinal cord. Some neurons expressing dsAAV2 and located in the spinal cord dorsal horn area were also positive for NeuN ( Fig. 1 C and D) . In the nearby L2 DRG, Ϸ30% of the CGRP-positive cells coexpressed MORS196A-EGFP, and these cells were either small or intermediate-sized neurons ( Fig. 1 E and F) . Although we did not stain for endogenous MOR expression in these neurons because the epitopes of the endogenous receptor and the exogenous MOR mutant are similar, its pattern of distribution was in accord with those reported (11) .
dsAAV2 Did Not Alter the Acute or Chronic Response to Morphine. The injection of dsAAV2 might result in spinal cord injury or an increase morphine efficacy as suggested in a previous report (12) . Therefore, before we examined the possible activation of the mutant receptors by classical opioid antagonists, we determined whether mice injected with dsAAV2 responded differently to morphine. To eliminate the mice with spinal cord injuries after dsAAV2 injections, basal tail-flick latencies were determined before and 2-4 weeks after the injection. Only mice with similar basal tail-flick latency before and after the dsAAV2 injection were used in subsequent studies. Using these criteria, we excluded Ϸ4% of the mice. The Von Frey test was also performed, and significant hyperalgesia (P Ͻ 0.05) was observed 3 days after the dsAAV2 injection, but no hyperalgesia was observed 6 days after virus injection. In mice that were injected with MORS196A-EGFP dsAAV2, the antinociceptive effects of morphine did not change before or after gene transfer compared with the morphine effects in mice injected either with saline (control) or with EGFP dsAAV2 (Table 1) . When the ED 50 values for morphine were determined by using the up-down method (13) , morphine exhibited similar potency in eliciting the antinociceptive response, at Ϸ1.5 mg/kg, regardless of the type of dsAAV2 injected. Interestingly, in contrast to a previous report (12) , the injection of wild-type MOR-EGFP dsAAV2 neither increased the potency nor prolonged the action of morphine ( Table 1) . As expected, when these mice were injected with morphine 10 mg/kg s.c. twice daily for 6 days, the potency of morphine in inhibiting the tail-flick response was dramatically reduced. There was an Ϸ5-fold increase in the ED 50 value for morphine in inhibiting the tail-flick response in mice injected with MORS196A-EGFP dsAAV2, which was similar to the observed increase in mice injected with other control dsAAV2 (Table 1) . Therefore, neither the injection procedure nor the gene transferred by dsAAV2 into the lumbar spinal cord dorsal horn region altered the acute and chronic responses to morphine in these mice.
Naloxone Elicited Antinociceptive Effects Without Tolerance in Mice
Injected with MORS196A-EGFP dsAAV2. In MORS196A knockin mutant mice, acute treatment with an opioid antagonist resulted in an antinociceptive response (2) . If the dsAAV2-mediated transfer of MORS196A-EGFP results in expression in the nociceptive neurons in the lumbar/sacral spinal cord dorsal horn area, activation of the mutant receptor by naloxone should result in the inhibition of the tail-flick response. Before the transfer of MORS196A-EGFP, naloxone (10 mg/kg s.c.) did not produce a significant antinociceptive effect in these ICR mice [area under the curve (AUC) ϭ 58.2 Ϯ 4.4 min ϫ s], as shown in Fig. 2 A and C. However, 4 weeks after the transfer of MORS196A-EGFP, 31 of 40 (77.5%) mice injected showed an AUC Ն150, and 26 of 40 (65%) mice showed an AUC Ն200 (Fig. 2C) . We decided to choose mice with AUC Ն200 for the subsequent behavioral tests. In these mice, the antinociceptive effects of naloxone were observed from 7 days after MORS196A-EGFP gene transfer and lasted for at least 6 months (Fig. 2D) . Conversely, when saline (control), EGFP dsAAV2, or MOR-EGFP dsAAV2 was injected into S2/S3 spinal cord, the mice showed no significant antinociceptive effect to naloxone 4 weeks after virus injection (Fig. 3A) . In mice injected with MORS196A-EGFP dsAAV2, the ED 50 of naloxone in inhibiting the tail-flick latency was 8.3 Ϯ 1.7 mg/kg. In mice that had been injected with saline, EGFP dsAAV2, or MOR-EGFP dsAAV2, no antinociceptive response was observed at the highest dose of naloxone tested, 40 mg/kg. These results clearly indicate that the observed naloxone antinociceptive effect was a direct result of dsAAV2-mediated MORS196A-EGFP gene transfer. Moreover, this naloxone effect could be blocked by the peptide MOR antagonist CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH 2 ), which was shown to be incapable to activate the Ser 196 mutant in our earlier studies (1) . When 100 ng of CTOP was injected intrathecally (i.t.) before naloxone was injected s.c., this peptide antagonist blocked the naloxone-induced antinociceptive response in mice injected with MORS196A-EGFP dsAAV2 (Fig. 3B) . Interestingly, unlike chronic morphine treatment, after mice were injected with naloxone (10 mg/kg s.c.) twice daily for 6-7 days, neither the magnitude (AUC ϭ 250 Ϯ 20 min ϫ s) nor the potency (ED 50 ϭ 10 Ϯ 1.3 mg/kg) of naloxone differed significantly from the acute magnitude and potency values (Fig. 3A) . Hence, chronic naloxone treatment did not induce receptor tolerance as morphine did.
The Naloxone Antinociceptive Effect Is at the Spinal Level and Not at the Supraspinal Level in Mice Injected with MORS196A-EGFP. To demonstrate that the observed antinociceptive effects of naloxone were a direct result of dsAAV2-mediated gene transfer, we injected naloxone i.t. (5 g) or intracerebroventricularly (i.c.v., 10 g) to determine whether it induced the antinociceptive effects at these two sites. Naloxone exhibited an antinociceptive effect only when it was given i.t. but not when it was injected i.c.v. (Fig. 2B) . We also used the hot-plate test to discriminate the supraspinal from the spinal cord antinociception induced by naloxone. If the MORS196A-EGFP expressed in the spinal cord dorsal horn area was responsible for the observed naloxone response, the absence of this mutant receptor expression at the supraspinal level predicts a lack of naloxone effect in the hot-plate test. Therefore, mice injected with MORS196A-EGFP dsAAV2 that exhibited an antinociceptive response to naloxone in the tail-flick test 4 weeks after injection were used in the hot-plate study. In these mice, morphine (10 mg/kg s.c.) produced a significant antinociceptive effect (AUC ϭ 750 Ϯ 59 min ϫ s). However, in contrast to the tail-flick test, naloxone (10 mg/kg s.c.) did not produce any measurable antinociceptive effect in these mice (AUC ϭ 56 Ϯ 8.3 min ϫ s) in the hot-plate test. Thus, the appearance of naloxone antinociceptive activity in mice injected with MORS196A-EGFP correlated directly with the location at which the mutant receptor was injected.
Morphine but Not Naloxone Induced Physical Dependence and Reward
Effects in Mice Injected with MORS196A-EGFP. Two of the side effects of morphine are a tendency to develop physical depen- The ED50 values of morphine to inhibit the tail-flick responses were determined before gene transfer by the up-down method. After 4 weeks of gene transfer, animals were tested for the ED 50 values of morphine again and then chronically treated with morphine (10 mg/kg s.c., twice per day for 6 days). The ED50 values were then redetermined. The values represent the mean Ϯ SEM (n ϭ 6 -8). dence and addiction after chronic administration. If our current paradigm using the opioid antagonist naloxone to activate the mutant MORS196A receptor is to be developed further for pain management, its addiction potential must be evaluated. Therefore, physical dependence on morphine and naloxone was evaluated in control and MORS196A-EGFP-injected mice. The natural withdrawal signs after chronic morphine or naloxone treatment were evaluated to access potential physical dependence. In the MORS196A-EGFP-dsAAV2-injected mice, chronic morphine treatment (10-50 mg/kg s.c. twice per day for 6 days) induced significant spontaneous withdrawal behaviors 14 or 38 h after the withdrawal of morphine. However, chronic treatment with naloxone (10-50 mg/kg s.c. twice per day for 6 days) did not elicit any spontaneous withdrawal signs (Fig. 4A) .
Whether morphine or naloxone produce reward effects in mice injected with MORS196A-EGFP dsAAV2 was determined by the conditioned place preference (CPP) test in another group of animals. As shown in Fig. 4B , in control mice the administration of 5 mg/kg morphine i.p. and conditioning for 6 days markedly increased the time spent in the morphine-paired compartment (220 Ϯ 39 s; P Ͻ 0.001), indicating that morphine had a significant reward effect on these control mice. Chronic naloxone treatment did not result in any reward effect on the control mice. In the MORS196A-EGFP-dsAAV2-injected mice, chronic morphine produced a similar drug reward effect, and the time spent in the morphine-paired compartment increased to 190 Ϯ 14 s (P Ͻ 0.001). Although acute naloxone produced an antinociceptive response in these mice, chronic naloxone (10 mg/kg i.p.) did not elicit a drug reward effect in the MORS196A-EGFP-dsAAV2-injected mice (Fig. 4B) . Thus, in contrast to morphine, chronic naloxone treatment did not produce reward effects in these mice.
Discussion
In this study we provide an alternative approach to developing novel analgesic compounds to resolve the problem of opioid tolerance and dependence. We used a novel gene transfer vector, dsAAV2, to transfer and locally express the MORS196A mutant receptor, which has been shown to be activated by opioid alkaloid antagonists. This approach was based on a fundamental property of opioid alkaloid antagonists, i.e., that by themselves, without the presence of an agonist or the activation of the endogenous opioid peptide systems, there is no measurable physiological or pharmacological response to the antagonists. Furthermore, the coadministration of morphine with the ␦-opioid antagonist, thus inactivating the ␦-opioid receptor (DOR), blocks morphine tolerance in animals (14) . The absolute dependence on DOR activity for tolerance development during chronic morphine treatment was demonstrated unequivocally in the DOR Ϫ/Ϫ null mouse (15) . Therefore, it is reasonable to surmise that, if an antagonist that can activate the exogenously delivered and expressed mutant receptor is administered, the same antagonist can inactivate the endogenous MOR and DOR, and subsequent tolerance and dependence responses should be avoided. These were exactly our observations. The expression of the MORS196A-EGFP mutant receptor in the dorsal horn region of the spinal cord (up to L2/L3 and down to Co2) within the ascending pain pathway of the spinothalamic tract resulted in the production by naloxone of an antinociceptive response, as measured by the tail-flick test. That these antagonist-mediated antinociceptive responses were indeed the consequence of transgene expression was concluded from the observations that (i) the injection of dsAAV2 containing the wild-type MOR at the same site did not produce naloxone-induced antinociception; (ii) the antagonist-mediated antinociception could be blocked by the MOR peptide antagonist CTOP; (iii) the i.c.v. injection of naloxone did not produce an antinociceptive response, whereas i.t. injection of the antagonist did; and (iv) other antinociceptive tests, such as the hot-plate test, which monitors the activation of the opioid receptor within the descending pain-inhibiting tract in the dorsolateral funiculus, did not reveal any naloxone-induced antinociception. Furthermore, as expected, chronic activation of the exogenously introduced MORS196A-EGFP mutant receptor by an antagonist did not result in the development of tolerance, physical dependence, and reward responses. In contrast, chronic morphine treatment of the same animals resulted in the development of all three responses. Such observations parallel those obtained with the MORS196A knockin mouse in which the failure of chronic naloxone treatment to produce tolerance was demonstrated to result from the inactivation of DOR and the activation of the MORS196A mutant receptor by the antagonist (16) . Thus, the use of an antagonist to activate the mutant MOR did not entail the development of tolerance and dependence associated with morphine treatment.
In the construct described here, the expression of the transgene was under the control of the CMV promoter. The expression of the transgene in all types of neurons could confound the pharmacology of morphine. In this study, the gene vector injected into the spinal cord parenchyma was taken up by sensory nerve terminals. Some of the MORS196A-EGFP was also coexpressed with NeuN (a neuronal marker) in the neurons of the spinal cord dorsal horn. These results indicate that MORS196A can be expressed not only in the primary sensory neurons, but also in the secondary projection neurons and many other neurons that might not be related to pain control. Although almost every mouse showed EGFP expression in the sacral spinal cord and up to certain level of lumbar or down to Co2 spinal cord after gene delivery, the level of EGFP expression was not uniform. Nevertheless, 31 of 40 (77.5%) mice responded to naloxone and demonstrated a significant antinociceptive effect measured by the tail-flick test. The relatively low percentage of CGRP-positive neurons expressing MORS196A-EGFP did not correlate with such a relatively high percentage of mice exhibiting a naloxone-induced antinociceptive effect. Perhaps the expression of MORS196A in neurons related to the pain pathway was sufficiently high to elicit an antinociceptive response but could not be detected by EGFP fluorescence. Such a scenario has a precedent in our previous study with MORS196A knockin mice. The MOR levels in these mutant mice were 10% of that in wild-type mice, but neither the potency nor the efficacy of morphine was altered in these mice (2) . With the absence of tolerance, physical dependence, and reward effects in mice injected with the MORS196A-EGFP construct during antagonist activation, we have developed a new pain management paradigm with minimal side effects. However, to develop our current technique further toward a therapeutic application, the expression of the transgene must be limited to the nociceptive neurons in which MOR is expressed endoge- nously. This control of transgene expression could be accomplished by the replacement of the current CMV promoter with the 5Ј upstream promoter region of the MOR gene, which has been shown to control the spatial expression of the receptor transcript (17) . Even with the ability to control the spatial expression of the transgene, we must also improve the efficacy of the antagonist. From our other reported study, it is clear that opioid alkaloid antagonists behave like partial agonists in the MORS196A mutant (18) . Although the molecular mechanism remains unresolved, the introduction of additional mutations into the seventh transmembrane domain of MOR could increase the efficacy of the antagonist (18) . Therefore, in our future strategy to develop a better therapy for pain control, we must first combine the necessary receptor mutations to generate a MOR mutant in which opioid alkaloids have full agonistic properties. The expression of such a mutant receptor will be controlled by the 5Ј elements that control MOR expression endogenously. Second, the use of viral vectors, such as adenovirus, for gene therapy has met with some resistance because of some unfavorable press but remains a viable approach altering eventual treatment outcomes. However, the injection of the gene intraparenchymally is not the ideal paradigm for future therapeutic purposes. A less invasive method of gene delivery, such as i.t. injection of the virus into the subarachnoid space of the spine, must be developed. Moreover, if such a mutant receptor is to be used in pain management, the use of antagonists to activate the mutant receptor could have adverse effects in patient populations that are taking chronic pain medicines, namely, the opioid analgesics. A carefully designed regimen must be developed in which the patient will gradually be weaned from opioid agonists before any opioid antagonists are used to activate the transgene. All of these and other challenges must be met before the eventual use of MOR mutants as a pain treatment paradigm.
Materials and Methods
Construction and Production of dsAAV2 Vector. The original dsAAV-CMV-EGFP shuttle vector was obtained from Xiao Xiao (University of North Carolina, Chapel Hill, NC). The plasmid dsAAV-CMV-MOR-EGFP or MORS196A-EGFP was constructed by replacing the GFP gene and the SV40 polyA site of dsAAV-CMV-EGFP with the MOR-EGFP or MORS196A-EGFP cDNA at BamHI and NotI sites, coupled to a miniature polyA site. The recombinant viral stocks were produced by the adenovirus-free, triple-plasmid cotransfection method (5). The AAV vectors were purified by double CsCl centrifugation, and the titers were determined by dot blot assay in the range of 1.0-3.0 ϫ 10 13 viral particles per milliliter. Each dsAAV particle was calculated to contain two copies of the single-stranded viral genome (vs. one copy in each conventional ssAAV particle). All AAV vectors used in this study were from AAV serotype 2.
Animals. Male ICR mice (30-35 g) were used in this study. All mice were kept in an animal room with a 12-h light/dark cycle at a temperature of 25 Ϯ 2°C and humidity of 55%. A standard diet and water were provided ad libitum. The care of animals was carried out in accordance with institutional and international standards (Principles of Laboratory Animal Care, National Institutes of Health), and the protocol had the approval of the Institutional Animal Care and Use Committee of the National Defense Medical Center (Taiwan, Republic of China). There were at least eight mice in each group.
Direct Microinjection of dsAAV Vectors into Spinal Cord Dorsal Horn.
Mice were anesthetized with pentobarbital (110 mg/kg i.p.). After anesthesia, the mice were placed under a dissecting microscope and a partial dorsal laminectomy was performed. One of the lumbar processes at L2 was carefully removed to expose a segment of the spinal cord (S2/S3). The mouse was then placed in a spinal frame holder and mounted under a stereotaxic frame with a microinjector attachment that includes a 10-l Hamilton syringe with a microtipped glass pipette. Four 0.5-l injections of saline (control), EGFP dsAAV2, MOR-EGFP dsAAV2, or MORS196A-EGFP dsAAV2 (4.5 ϫ 10 12 viral particles per milliliter) were injected bilaterally at a depth of Ϸ0.3-0.4 mm (spinal cord dorsal horn). After surgery, the muscle and skin around the wound were sutured and three microsurgical wound clips were applied.
Determination of the Drugs' Antinociceptive Effects. Tail-flick test.
Drug-induced antinociception was evaluated by using the tailflick test (19) . Using a tail-flick apparatus (Ugo Basile), the basal tail-flick latency of most mice was 3-4 s. A cutoff time of 10 s was used to avoid tissue damage. The area under the timeresponse curve (AUC) (20) or the ED 50 value was used as an index of the antinociceptive effect of the drug(s). To determine the AUC, tail-flick latency was recorded at 30, 60, 90, 120, and 180 min after s.c. drug administration or at 10, 20, 30, 60, and 90 min after i.t. or i.c.v. drug administration. For i.t. injections, drugs (5 l) were administered with a 30-gauge needle, which was inserted into the intrathecal space in the cauda equina region as described (21) . For i.c.v. injections, drugs (1 l) were administered with a 26-gauge needle, which directly punctured the lateral ventricle. The AUC value was obtained by calculating the area under the time-response curve of the antinociceptive effect (test latency Ϫ basal latency) from 0 to 180 min after the administration of the drugs (Fig. 2 A) . The ED 50 was determined by the up-down method described by Dixon (13) . Briefly, a series of test levels was chosen with equal spacing between each log dose of drug (0.71-15.85 mg/kg). Then a series of trials (n Ͼ 5) was performed following the rule that the drug dose was reduced after inhibition of the tail-flick response and the drug dose was increased after no inhibition of the tail-flick response. Each mouse underwent only one trial. The ED 50 value was derived from the equation ED 50 ϭ X f ϩ k ϫ d, where X f is the last dose administered, k is the tabular value outlined by Dixon (13) , and d is the interval between doses. The antinociceptive effect was expressed as a percentage of the maximal possible effect (%MPE) according to the following equation: %MPE ϭ [(test latency) Ϫ (baseline latency)/(10 Ϫ baseline latency)] ϫ 100. The animal responses were quantified by defining significant inhibition as a tail-flick response with a %MPE of 50% or greater.
Before microinjection of the vector, the antinociceptive effect of saline, morphine (10 mg/kg s.c.), or naloxone (10 mg/kg s.c.) was tested as the pretest data. The acute antinociceptive effect of each drug was tested again 4 weeks after gene transfer. To estimate drug-induced tolerance, the mice were then injected with morphine (10 mg/kg s.c. twice per day) or naloxone (10 mg/kg s.c. twice per day) for 6-7 days. The ED 50 (tested on the seventh day) and AUC (tested in the eighth day) values of the drug(s) were evaluated. Hot-plate test. The antinociceptive effect of each drug was evaluated by a hot-plate apparatus (Digital DS-37 Socrel model) with a 25 ϫ 25-cm 2 metal surface maintained at 50 Ϯ 0.5°C surrounded by a 30-cm-high Plexiglas wall (22) . Latency (in seconds) was considered the time elapsed until the animal either licked or shook its hind paw or jumped after it was placed on the hot-plate surface. A cutoff time of 30 s was used to avoid tissue damage to the animal. Test latency was determined at 30, 60, and 90 min after drug injection. The AUC values of the drug(s) were calculated.
Determination of Physical Dependence. Natural withdrawal symptoms were assessed to determine the physical dependence on each drug in the different groups. Two weeks after MORS196A-EGFP gene transfer, the mice were treated daily with increasing doses of morphine or naloxone (10, 15, 20, 30 , 40, and 50 mg/kg s.c.) twice a day for 6 days. The somatic signs of opiate withdrawal (jump, paw tremor, wet dog shaking, teeth chattering, diarrhea, ptosis, piloerection) were counted for 30 min at 14 and 38 h after the last dose of the drug was injected. Jump and paw tremor frequencies were recorded during the test time, and a score of 1 was assigned to every three jumps or five paw tremors. Diarrhea and ptosis events were recorded for every 5-min interval in which they occurred (maximal score ϭ 6). The presence or absence of piloerection was noted. A total opiate natural withdrawal score was calculated by summing the values for each sign (23) .
CPP Test. Drug reward effect were measured by the CPP test as described previously, except that the size of the apparatus here was adjusted for mice (24) . The CPP test apparatus was divided into three compartments. Two identically sized compartments (15 ϫ 15 ϫ 15 cm 3 ) were constructed on either side, separated by a narrower compartment (3 ϫ 15 ϫ 15 cm 3 ) with guillotine doors. For CPP conditioning, the mice were given saline in the morning and morphine (5 mg/kg i.p.) or naloxone (10 mg/kg i.p.) in the afternoon for 6 days. A distinctive environment (red light with walls covered by white paper) was paired repeatedly with the saline injections, and a different environment (blue light with walls covered by mosaic-type paper) was associated with drug injections. The animals were kept for 40 min in the corresponding compartment with the guillotine doors closed. We determined the place preference before conditioning and on the day after conditioning (day 7) by placing the mice into the CPP test apparatus with the guillotine doors open for 15 min. The times that the mice stayed in each compartment were recorded. The measurement of the drug reward effect was determined by the increase in the time spent in the compartment previously paired with drug injection relative to that spent in the saline-paired compartment.
Immunohistochemistry. Mice were anesthetized with chloral hydrate (400 mg/kg i.p.) and perfused transcardially with Tyrode's calcium-free buffer (116 mM NaCl/5.36 mM KCl/1.57 mM MgCl 2 ⅐6H 2 O/0.405 mM MgSO 4 /1.23 mM NaH 2 PO 4 /5.55 mM glucose/26.2 mM NaHCO 3 , pH 7.4), followed by 4% paraformaldehyde in 0.1 M phosphate buffer. The spinal cord and DRG were dissected and then placed in 20% sucrose solution overnight at 4°C. The samples were then embedded in OCT compound and frozen immediately at Ϫ80°C. Serial transverse spinal cord slices and DRG (10 m) were sectioned with a cryostat. The slices were mounted on SuperFrost Plus slides (Menzel-Glaser) and the EGFP expression was visualized with a fluorescence microscope. For immunohistochemistry, antibodies were diluted in blocking buffer (0.1 M PBS containing 1% goat serum and 0.1% Triton X-100). Anti-NeuN antibody (MAB377; Chemicon) was used at a dilution of 1:500, and anti-CGRP antibody (AB5920; Chemicon) was used at a dilution of 1:2,000. Secondary antibody directed against rabbit or mouse IgG coupled to rhodamine for immunofluorescence detection (Jackson) was diluted 1:200. Sections were then washed with PBS, cleared, and coverslipped by using mounting medium (Serotec, HIS002B). The processed sections were examined with an fluorescence instruments (model BH2-RFL-T3; Olympus) on an upright microscope and an Olympus BX50 camera with SPOT software (version 4.6; Diagnostic Instruments).
Statistical Analysis. Data are expressed as means Ϯ SEM. Oneway ANOVA and the Newman-Keuls test were used to analyze the data. A difference was considered to be significant when P Ͻ 0.05.
